Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Recent & Breaking News (NDAQ:MRNA)

Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates

Accesswire May 4, 2023

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting

Accesswire May 3, 2023

Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines

Accesswire May 2, 2023

Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

Accesswire April 20, 2023

Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science

Accesswire April 20, 2023

Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA

Accesswire April 16, 2023

Moderna Announces Clinical and Program Updates at 4th Vaccines Day

Accesswire April 11, 2023

MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

Accesswire April 6, 2023

Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility

Accesswire March 30, 2023

Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023

Accesswire March 24, 2023

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

GlobeNewswire March 23, 2023

Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting

Accesswire March 14, 2023

Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023

Accesswire March 10, 2023

Moderna to Present at Cowen's 43rd Annual Health Care Conference

Accesswire February 28, 2023

Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates

Accesswire February 23, 2023

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection

Accesswire February 22, 2023

Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

Accesswire February 22, 2023

Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)

Accesswire February 17, 2023

Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate

Accesswire February 16, 2023

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform(TM) in Personalized mRNA Cancer Vaccine Clinical Trials

Business Wire February 3, 2023